sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
|
Accutane
|
tetracyclines
|
ADVISE
|
Isotretinoin_ddi.xml
|
DDI-DrugBank.d163.s2
|
DDI-DrugBank.d163.s2.p4
|
In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
|
felbamate
|
phenytoin
|
ADVISE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s15
|
DDI-DrugBank.d434.s15.p2
|
Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
|
live vaccines
|
RAPTIVA
|
ADVISE
|
Efalizumab_ddi.xml
|
DDI-DrugBank.d44.s2
|
DDI-DrugBank.d44.s2.p4
|
ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
|
ketoconazole
|
indinavir
|
NONE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s2
|
DDI-DrugBank.d380.s2.p4
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
anticonvulsants
|
Sporanox
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p258
|
FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
|
alcohol
|
CNS depressants
|
NONE
|
Cyclobenzaprine_ddi.xml
|
DDI-DrugBank.d150.s1
|
DDI-DrugBank.d150.s1.p4
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
quinine
|
warfarin sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1429
|
When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
|
digoxin
|
BREVIBLOC
|
MECHANISM
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s4
|
DDI-DrugBank.d422.s4.p0
|
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
|
DOSTINEX
|
thioxanthines
|
ADVISE
|
Cabergoline_ddi.xml
|
DDI-DrugBank.d282.s0
|
DDI-DrugBank.d282.s0.p2
|
Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
|
Simulect
|
mycophenolate mofetil
|
NONE
|
Basiliximab_ddi.xml
|
DDI-DrugBank.d544.s4
|
DDI-DrugBank.d544.s4.p1
|
Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
|
corticosteroids
|
diuretics
|
ADVISE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s1
|
DDI-DrugBank.d314.s1.p4
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
felodipine
|
mirtazapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p665
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
magnesium salicylate
|
bismuth subsalicylate
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p73
|
Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
|
Quinidine
|
nisoldipine
|
MECHANISM
|
Nisoldipine_ddi.xml
|
DDI-DrugBank.d106.s8
|
DDI-DrugBank.d106.s8.p0
|
Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
|
Antibiotics
|
amoxicillin
|
NONE
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s11
|
DDI-DrugBank.d367.s11.p3
|
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
|
erythromycins
|
penicillins
|
EFFECT
|
Ampicillin_ddi.xml
|
DDI-DrugBank.d211.s2
|
DDI-DrugBank.d211.s2.p11
|
Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
|
phenobarbital
|
diclofenac
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s17
|
DDI-DrugBank.d249.s17.p2
|
Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
|
ertapenem
|
probenecid
|
MECHANISM
|
Ertapenem_ddi.xml
|
DDI-DrugBank.d329.s1
|
DDI-DrugBank.d329.s1.p0
|
Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
|
Amphetamines
|
antihypertensives
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s15
|
DDI-DrugBank.d236.s15.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
felbamate
|
haloperidol
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p631
|
Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
|
Amphetamines
|
meperidine
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s20
|
DDI-DrugBank.d236.s20.p2
|
Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
|
aspirin
|
carbonic anhydrase inhibitors
|
ADVISE
|
Dichlorphenamide_ddi.xml
|
DDI-DrugBank.d36.s0
|
DDI-DrugBank.d36.s0.p0
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
furosemide
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s13
|
DDI-DrugBank.d210.s13.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
clofibrate
|
Atromid-S
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p665
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
salicylates
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p13
|
Corticosteroids may increase the clearance of chronic high dose aspirin.
|
Corticosteroids
|
aspirin
|
EFFECT
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s4
|
DDI-DrugBank.d487.s4.p0
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
bromocriptine
|
lovastatin
|
NONE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p51
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
nicotinamide
|
quinupristin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p318
|
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
|
18-MC
|
nicotine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s6
|
DDI-MedLine.d110.s6.p4
|
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
|
magnesium
|
magnesium
|
NONE
|
7786695.xml
|
DDI-MedLine.d103.s1
|
DDI-MedLine.d103.s1.p10
|
Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
|
lincomycin
|
erythromycin
|
EFFECT
|
Lincomycin_ddi.xml
|
DDI-DrugBank.d130.s2
|
DDI-DrugBank.d130.s2.p0
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
monoamine oxidase inhibitors
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p17
|
Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
|
REVIA
|
opioid analgesics
|
EFFECT
|
Naltrexone_ddi.xml
|
DDI-DrugBank.d346.s4
|
DDI-DrugBank.d346.s4.p1
|
Hydrocodone increases gabapentin AUC values by 14%.
|
Hydrocodone
|
gabapentin
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s24
|
DDI-DrugBank.d438.s24.p0
|
Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
|
anti-inflammatory
|
ibuprofen
|
NONE
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s9
|
DDI-DrugBank.d367.s9.p11
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
ethosuximide
|
fluoxetine
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p153
|
Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
|
dexamethasone
|
albendazole
|
MECHANISM
|
Albendazole_ddi.xml
|
DDI-DrugBank.d321.s0
|
DDI-DrugBank.d321.s0.p5
|
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
|
Tricyclic antidepressants
|
clonidine
|
EFFECT
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s2
|
DDI-DrugBank.d224.s2.p0
|
Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
|
barbiturates
|
ethchlorvynol
|
EFFECT
|
Ethchlorvynol_ddi.xml
|
DDI-DrugBank.d405.s1
|
DDI-DrugBank.d405.s1.p4
|
Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
|
Nelfinavir
|
amprenavir
|
MECHANISM
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s8
|
DDI-DrugBank.d437.s8.p0
|
Coadministration of NIZORAL Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
|
NIZORAL
|
triazolam
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s12
|
DDI-DrugBank.d458.s12.p1
|
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
|
Diazepam
|
morphine
|
EFFECT
|
11210678.xml
|
DDI-MedLine.d67.s5
|
DDI-MedLine.d67.s5.p0
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Prolixin
|
trimeprazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p145
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
procainamide
|
quinidine
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p119
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
indinavir
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p6
|
or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
|
zinc
|
quinolone
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s16
|
DDI-DrugBank.d395.s16.p2
|
Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
|
Quinolones
|
warfarin
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s5
|
DDI-DrugBank.d217.s5.p2
|
Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
|
hormonal contraceptives
|
acetaminophen
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s3
|
DDI-DrugBank.d485.s3.p0
|
Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
|
Sympathomimetic amines
|
methyldopa
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s2
|
DDI-DrugBank.d389.s2.p2
|
Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
|
Oxytocin
|
dinoprost
|
EFFECT
|
Dinoprost Tromethamine_ddi.xml
|
DDI-DrugBank.d181.s0
|
DDI-DrugBank.d181.s0.p1
|
Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
|
astemizole
|
itraconazole
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s6
|
DDI-DrugBank.d165.s6.p5
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
|
anticoagulant
|
adrenocortical steroids
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s6
|
DDI-DrugBank.d64.s6.p0
|
Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
|
praziquantel
|
albendazole sulfoxide
|
MECHANISM
|
Albendazole_ddi.xml
|
DDI-DrugBank.d321.s1
|
DDI-DrugBank.d321.s1.p3
|
Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
|
diclofenac
|
aspirin
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s0
|
DDI-DrugBank.d249.s0.p9
|
Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
|
fluvoxamine
|
Xanax
|
ADVISE
|
Adinazolam_ddi.xml
|
DDI-DrugBank.d449.s1
|
DDI-DrugBank.d449.s1.p4
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
dexamethasone
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p3
|
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
|
Methamphetamine
|
pargyline
|
EFFECT
|
3871245.xml
|
DDI-MedLine.d73.s4
|
DDI-MedLine.d73.s4.p1
|
Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
|
diphenoxylate
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s5
|
DDI-DrugBank.d450.s5.p2
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
griseofulvin
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p13
|
Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
|
Targretin
|
gemfibrozil
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s4
|
DDI-DrugBank.d467.s4.p0
|
However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
|
EXTRANEAL
|
insulin
|
ADVISE
|
Icodextrin_ddi.xml
|
DDI-DrugBank.d501.s6
|
DDI-DrugBank.d501.s6.p0
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
carbamazepine
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p2
|
SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
|
RESIN
|
RESIN
|
NONE
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s5
|
DDI-DrugBank.d566.s5.p4
|
fluoxetine, fluvoxamine, paroxetine, sertraline).
|
paroxetine
|
sertraline
|
NONE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s8
|
DDI-DrugBank.d410.s8.p5
|
Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
|
ethosuximide
|
phenytoin
|
MECHANISM
|
Ethosuximide_ddi.xml
|
DDI-DrugBank.d205.s0
|
DDI-DrugBank.d205.s0.p15
|
Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45 (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
|
propranolol
|
ergotamine
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s3
|
DDI-DrugBank.d410.s3.p14
|
No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
|
chlordiazepoxide
|
warfarin
|
NONE
|
Nizatidine_ddi.xml
|
DDI-DrugBank.d475.s0
|
DDI-DrugBank.d475.s0.p14
|
WelChol decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
|
WelChol
|
Calan SR
|
MECHANISM
|
Colesevelam_ddi.xml
|
DDI-DrugBank.d551.s2
|
DDI-DrugBank.d551.s2.p1
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
cyclosporine
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p107
|
Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
|
TORADOL
|
carbamazepine
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s18
|
DDI-DrugBank.d3.s18.p6
|
Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
|
Echistatin
|
contortrostatin
|
EFFECT
|
10978746.xml
|
DDI-MedLine.d69.s3
|
DDI-MedLine.d69.s3.p0
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
valsartan
|
amlodipine
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p61
|
Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
|
tricyclic antidepressant
|
cimetidine
|
EFFECT
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s23
|
DDI-DrugBank.d223.s23.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
lidocaine
|
multivitamins
|
NONE
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p79
|
Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
|
fluvoxamine
|
diazepam
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s20
|
DDI-DrugBank.d76.s20.p0
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
chlorpromazine
|
tricyclic antidepressant
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p7
|
Cyclosporine, hexobarbital and phenytoin concentrations.
|
Cyclosporine
|
phenytoin
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s15
|
DDI-DrugBank.d53.s15.p1
|
Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
|
Amprenavir
|
ritonavir
|
EFFECT
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s13
|
DDI-DrugBank.d437.s13.p0
|
If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
|
nifedipine
|
cimetidine
|
ADVISE
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s14
|
DDI-DrugBank.d373.s14.p0
|
Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
|
warfarin
|
ketorolac tromethamine
|
MECHANISM
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s1
|
DDI-DrugBank.d3.s1.p18
|
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
|
phenobarbital
|
clonazepam
|
MECHANISM
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s5
|
DDI-DrugBank.d333.s5.p7
|
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
|
FOSCAVIR
|
amphotericin B
|
ADVISE
|
Foscarnet_ddi.xml
|
DDI-DrugBank.d511.s4
|
DDI-DrugBank.d511.s4.p5
|
Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
|
Diclofenac
|
lithium
|
MECHANISM
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s8
|
DDI-DrugBank.d249.s8.p3
|
Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
|
TCA
|
Duloxetine
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s10
|
DDI-DrugBank.d548.s10.p5
|
Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45 (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
|
dihydroergotamine mesylate
|
macrolide class
|
MECHANISM
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s5
|
DDI-DrugBank.d410.s5.p26
|
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
|
quinidine
|
tricyclic anti-depressants
|
NONE
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s9
|
DDI-DrugBank.d137.s9.p11
|
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
|
calcium
|
iron
|
NONE
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s1
|
DDI-DrugBank.d440.s1.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
aminoglycosides
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p16
|
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
|
(-)-NANM
|
morphine
|
EFFECT
|
3968644.xml
|
DDI-MedLine.d30.s7
|
DDI-MedLine.d30.s7.p1
|
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
|
prochlorperazine
|
CAMPTOSAR
|
EFFECT
|
Irinotecan_ddi.xml
|
DDI-DrugBank.d279.s8
|
DDI-DrugBank.d279.s8.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
theophylline
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p10
|
Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
|
Fluvoxamine
|
TCA
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s17
|
DDI-DrugBank.d238.s17.p0
|
The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
|
methylprednisolone
|
Aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s14
|
DDI-DrugBank.d382.s14.p4
|
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
|
etoposide
|
etoposide
|
NONE
|
Etoposide_ddi.xml
|
DDI-DrugBank.d194.s1
|
DDI-DrugBank.d194.s1.p7
|
Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
|
anileridine
|
phenothiazines
|
ADVISE
|
Anileridine_ddi.xml
|
DDI-DrugBank.d215.s0
|
DDI-DrugBank.d215.s0.p2
|
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
|
Clindamycin
|
neuromuscular blocking agents
|
EFFECT
|
Clindamycin_ddi.xml
|
DDI-DrugBank.d256.s0
|
DDI-DrugBank.d256.s0.p0
|
Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
|
Amprenavir
|
ritonavir
|
ADVISE
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s14
|
DDI-DrugBank.d437.s14.p0
|
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
|
cholestyramine
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s6
|
DDI-DrugBank.d450.s6.p19
|
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
|
picrotoxin
|
phentolamine
|
EFFECT
|
2857099.xml
|
DDI-MedLine.d27.s0
|
DDI-MedLine.d27.s0.p4
|
Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
|
nonsteroidal anti-inflammatory drugs
|
anti-coagulants
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s2
|
DDI-DrugBank.d529.s2.p5
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.